Iqvia (NYSE:IQV) updated its FY18 earnings guidance on Wednesday. The company provided EPS guidance of $5.35-5.60 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.34. The company issued revenue guidance of $8.45-8.65 billion, compared to the consensus revenue estimate of $8.53 billion.Iqvia also updated its Q1 guidance to $1.23-1.30 EPS.
Several equities research analysts have recently weighed in on the stock. Piper Jaffray Companies reiterated a hold rating and set a $103.00 price objective on shares of Iqvia in a research report on Thursday. JPMorgan Chase & Co. increased their price objective on shares of Iqvia from $115.00 to $120.00 and gave the stock an overweight rating in a research report on Thursday. Mizuho set a $97.00 price objective on shares of Iqvia and gave the stock a hold rating in a research report on Wednesday, January 24th. SunTrust Banks reiterated a hold rating and set a $110.00 price objective on shares of Iqvia in a research report on Monday, January 22nd. Finally, Zacks Investment Research cut shares of Iqvia from a buy rating to a hold rating in a research report on Friday, January 19th. Eight investment analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus target price of $109.91.
Shares of Iqvia (NYSE:IQV) opened at $101.57 on Friday. The company has a quick ratio of 1.22, a current ratio of 1.19 and a debt-to-equity ratio of 1.21. The company has a market cap of $21,772.17, a price-to-earnings ratio of 16.79, a price-to-earnings-growth ratio of 1.43 and a beta of 0.61. Iqvia has a twelve month low of $75.94 and a twelve month high of $110.67.
In other Iqvia news, major shareholder Cpp Investment Board Private H sold 7,497,807 shares of the firm’s stock in a transaction on Thursday, November 30th. The shares were sold at an average price of $102.00, for a total value of $764,776,314.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John Connaughton sold 1,163,191 shares of the firm’s stock in a transaction on Thursday, November 30th. The stock was sold at an average price of $102.00, for a total transaction of $118,645,482.00. The disclosure for this sale can be found here. Insiders sold 8,727,078 shares of company stock valued at $890,124,079 over the last 90 days. Corporate insiders own 6.40% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This piece was reported by Markets Daily and is the property of of Markets Daily. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at https://www.themarketsdaily.com/2018/02/16/iqvia-iqv-issues-fy18-earnings-guidance.html.
Iqvia Company Profile
IQVIA Holdings Inc, formerly Quintiles IMS Holdings, Inc, provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions, and workflow analytics and consulting services.
Receive News & Ratings for Iqvia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iqvia and related companies with MarketBeat.com's FREE daily email newsletter.